Report on how AI is driving market transformation - The global DNA sequencing market size is estimated to grow by USD 17.34 ...

Collaborations: Mersana continues to advance its Johnson & Johnson and Merck KGaA, Darmstadt, Germany collaborations. The ...

Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDG ...

Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic ...

Shares fall 19%. ([email protected]) 0612 ET – Merck KGaA should post higher 3Q earnings and sales, and investors will focus on the company’s prospects for its electronics division, which is boosted ...

This eases the user's understanding of the market thoroughly, while also gaining knowledge about Anxiety Disorder Treatment market opportunities and the dominant players Pfizer Inc, Merck KGaA, Sanofi ...

During the quarter Genmab's GEN1057, an investigational proprietary bispecific antibody and Merck KGaA's M5542, which is a ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” ...

The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...

Rahway, New Jersey Wednesday, November 13, 2024, 13:00 Hrs [IST] ...

The market for multiplex biomarker imaging is anticipated to reach a valuation of USD 1,631.4 million by 2034, up from USD ...